Tuesday, August 28, 2012

ALS MND Daily News Digest

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis
Neuralstem, Inc. (NYSE MKT: CUR) announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), with the eighteenth patient treated. This ...
See all stories on this topic »
Researchers make rare find in search of cure for ALS
Mass High Tech
Researchers in Belgium have made a rare discovery that may aid in finding a treatment for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Funded by the ALS Therapy Alliance, a non-profit in Boston, and Woonsocket, R.I.-based ...
See all stories on this topic »

No comments:

Post a Comment